{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:58:28Z","timestamp":1780336708175,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier","isbn-type":[{"value":"9780443293269","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.podrm.2023.11.006","type":"book-chapter","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T15:28:28Z","timestamp":1702481308000},"page":"115-151","source":"Crossref","is-referenced-by-count":4,"title":["Avanafil: A comprehensive drug profile"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.podrm.2023.11.006_bib1","unstructured":"Avanafil. Wikipedia, the free encyclopedia [cited 2023 4\/11]; from \u3008https:\/\/en.wikipedia.org\/wiki\/Avanafil\u3009."},{"key":"10.1016\/bs.podrm.2023.11.006_bib2","unstructured":"Avanafil. ChemSpider Search and share chemistry 11 April 2023; from \u3008http:\/\/www.chemspider.com\/Chemical-Structure.10676285.html?rid=685ca086\u20137bef-41da-8d63\u20131cf221f68072&page_num=0#synonymsTab\u3009."},{"key":"10.1016\/bs.podrm.2023.11.006_bib3","unstructured":"National Center for Biotechnology Information. \u201cPubChem Compound Summary for CID 87800810, Avanafil dibesylate\u201d PubChem., Accessed 10 April 2023; from \u3008https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Avanafil-dibesylate\u3009."},{"key":"10.1016\/bs.podrm.2023.11.006_bib4","unstructured":"FDA STENDRA\u00ae (avanafil) tablets for oral use. Initial US Approval: 2012; from \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/202276s018lbl.pdf\u3009."},{"key":"10.1016\/bs.podrm.2023.11.006_bib5","unstructured":"\u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spedra\u3009, Spedra. 2014."},{"key":"10.1016\/bs.podrm.2023.11.006_bib6","unstructured":"\u3008https:\/\/www.rsc.org\/Merck-Index\/monograph\/m2145\/avanafil?q=unauthorize\u3009. Avanafil Merck. from."},{"key":"10.1016\/bs.podrm.2023.11.006_bib7","unstructured":"\u3008http:\/\/www.chemspider.com\/Chemical-Structure.10676285.html\u3009. Avanafil ChemSpider. from."},{"key":"10.1016\/bs.podrm.2023.11.006_bib8","unstructured":"\u3008http:\/\/www.chemspider.com\/Chemical-Structure.34984746.html?rid=23bc3773-d7c1\u20134777-b451-a9f80e4492ef\u3009. Avanafil dibenzenesulfonate ChemSpider. from."},{"key":"10.1016\/bs.podrm.2023.11.006_bib9","unstructured":"Avanafil. The name THE MERCK INDEX is owned by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA, and is licensed to The Royal Society of Chemistry for use in the USA and Canada. 11 April 2023; from \u3008https:\/\/www.rsc.org\/Merck-Index\/monograph\/m2145\/avanafil?q=unauthorize\u3009."},{"key":"10.1016\/bs.podrm.2023.11.006_bib10","unstructured":"S.T. Rajan, S. Eswaraiah, K. Satyanarayana, Process for the preparation of (s)-4-[(3-chloro-4-methoxybenzyl)amino]-2-[2- (hydroxymethyl)-1-pyrrolidinyl]-n-(2-pyrimidinyl methyl-5-pyrimidine carboxamide. 2014, WO2015001567A1."},{"key":"10.1016\/bs.podrm.2023.11.006_bib11","first-page":"701","article-title":"Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility","volume":"10","author":"Katz","year":"2014","journal-title":"Ther. Clin. Risk Manag."},{"issue":"1","key":"10.1016\/bs.podrm.2023.11.006_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/1756287212466282","article-title":"Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties","volume":"5","author":"Kedia","year":"2013","journal-title":"Ther. Adv. Urol."},{"issue":"1","key":"10.1016\/bs.podrm.2023.11.006_bib14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijpharm.2016.08.044","article-title":"Effect of different polymers on avanafil\u2013\u03b2-cyclodextrin inclusion complex: in vitro and in vivo evaluation","volume":"512","author":"Soliman","year":"2016","journal-title":"Int. J.\u00a0Pharmaceut."},{"key":"10.1016\/bs.podrm.2023.11.006_bib15","unstructured":"Attachment 1: Product information for AusPAR Spedra\u00ae Avanafil A.Menarini Australia Pty Ltd PM-2014-02782-1-3. 27 October 2016; from \u3008https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-avanafil-161027-pi.pdf\u3009."},{"key":"10.1016\/bs.podrm.2023.11.006_bib16","unstructured":"Stendra (avanafil) prescribing information. Vivus, Inc. Accessed from 11 April 2023; from \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/202276s007lbl.pdf\u3009."},{"key":"10.1016\/bs.podrm.2023.11.006_bib17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ejps.2016.08.050","article-title":"Formulation of avanafil in a solid self-nanoemulsifying drug delivery system for enhanced oral delivery","volume":"93","author":"Soliman","year":"2016","journal-title":"Eur. J.\u00a0Pharmaceut. Sci."},{"issue":"8","key":"10.1016\/bs.podrm.2023.11.006_bib18","doi-asserted-by":"crossref","DOI":"10.1149\/1945-7111\/ac1d7d","article-title":"An eco-friendly solid-state electrode modified With ZnO nanoparticles decorated with MWCNT as an electrochemical sensor for the determination of avanafil in pure form, dosage form and human plasma","volume":"168","author":"Ali","year":"2021","journal-title":"J.\u00a0Electrochem. Soc."},{"key":"10.1016\/bs.podrm.2023.11.006_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2022.108261","article-title":"Anatase titanium oxide nanoparticles and multi-walled carbon nanotubes-modified carbon paste electrode for simultaneous determination of avanafil and doxorubicin in plasma samples","volume":"185","author":"Ali","year":"2023","journal-title":"Microchem. J."},{"key":"10.1016\/bs.podrm.2023.11.006_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2021.106895","article-title":"Hybrid NiO nanostructured\/sulfanilamide polymeric film for studying possible pharmacokinetic interaction between avanafil and nimodipine in real human serum by their simultaneous determination using square-wave voltammetry","volume":"172","author":"Ali","year":"2022","journal-title":"Microchem. J."},{"key":"10.1016\/bs.podrm.2023.11.006_bib21","first-page":"5811","article-title":"Development and validation of new colorimetric method for the estimation of Avanafil in bulk and dosage form","volume":"5","author":"Kashyap","year":"2013","journal-title":"Int. J.\u00a0Pharm.\u00a0Technol."},{"key":"10.1016\/bs.podrm.2023.11.006_bib22","first-page":"6418","article-title":"First order derivative and dual wavelength spectrophotometry methods development and validation for simultaneous estimation of Avanafil and Dapoxentine hydrochloride in bulk and dosage form","volume":"6","author":"Kashyap","year":"2014","journal-title":"Int. J.\u00a0Pharm.\u00a0Technol."},{"issue":"3","key":"10.1016\/bs.podrm.2023.11.006_bib23","first-page":"649","article-title":"Multivariate approaches for simultaneous determination of avanafil and dapoxetine by UV chemometrics and HPLC-QbD in binary mixtures and pharmaceutical product","volume":"99","author":"Patel","year":"2016","journal-title":"J.\u00a0AOAC Int."},{"key":"10.1016\/bs.podrm.2023.11.006_bib24","article-title":"Native and synchronous fluorescence spectroscopy for determination of avanafil in presence of its co-formulated drug (dapoxetine hydrochloride): application to pharmaceutical product, biological fluid and content uniformity","volume":"229","author":"Mohamed","year":"2020","journal-title":"Spectrochim. Acta A\u00a0Mol.\u00a0Biomol. Spectrosc."},{"key":"10.1016\/bs.podrm.2023.11.006_bib25","article-title":"D-optimal design as a useful tool response surface methodology for the optimisation of signals from synchronous fluorescence prior to simultaneous determination of avanafil and tadalafil","volume":"235","author":"Abdel-Raoof","year":"2020","journal-title":"Spectrochim. Acta A\u00a0Mol.\u00a0Biomol. Spectrosc."},{"issue":"7","key":"10.1016\/bs.podrm.2023.11.006_bib26","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1039\/D0RA08216C","article-title":"Second derivative synchronous fluorescence determination of avanafil in the presence of its acid-induced degradation product aided by powerful Lean Six Sigma tools augmented with D-optimal design","volume":"11","author":"Attia","year":"2021","journal-title":"RSC Adv."},{"issue":"3","key":"10.1016\/bs.podrm.2023.11.006_bib27","first-page":"17","article-title":"Spectrofluorimetric method for the estimation of avanafil in bulk and their tablet dosage form","volume":"3","author":"Tailor","year":"2016","journal-title":"Res.\u00a0Rev. J.\u00a0Drug Form. Dev.\u00a0Produ."},{"key":"10.1016\/bs.podrm.2023.11.006_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/ajocs\/2019\/v6i419005","article-title":"Validated stability indicating HPTLC and UV-spectrophotometric techniques for the determination of avanafil","author":"Darwish","year":"2019","journal-title":"Asian J. Chem. Sci."},{"issue":"3","key":"10.1016\/bs.podrm.2023.11.006_bib29","first-page":"171","article-title":"Analytical method validation for estimation of avanafil and dapoxetine hydrochloride tablet dosage form by HPTLC method","volume":"4","author":"Shah","year":"2017","journal-title":"Pharm. Biol. Eval."},{"key":"10.1016\/bs.podrm.2023.11.006_bib30","first-page":"59","article-title":"Stability indicating HPLC method for analysis of avanafil using diode array detector","volume":"5","author":"Fahmy","year":"2016","journal-title":"Int. J. Adv. Pharm. Biol. Chem."},{"issue":"1","key":"10.1016\/bs.podrm.2023.11.006_bib31","article-title":"Development and validation of reverse phase high performance liquid chromatography method for quantitative estimation of Avanafil in tablet dosage form","volume":"1","author":"Jadhav","year":"2020","journal-title":"J.\u00a0Pharm. Innov."},{"issue":"18","key":"10.1016\/bs.podrm.2023.11.006_bib32","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1080\/10826076.2015.1087860","article-title":"RP-HPLC with time programmed fluorescence detection for quantitation of avanafil and dapoxetine hydrochloride: application to pharmaceutical dosage form and biological fluid","volume":"38","author":"Hegazy","year":"2015","journal-title":"J.\u00a0Liquid Chromatogr.\u00a0Related Technol."},{"issue":"3","key":"10.1016\/bs.podrm.2023.11.006_bib33","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1039\/C9RA08717F","article-title":"Core\u2013shell particles and monolithic columns; tools for simultaneous LC analysis of avanafil, sildenafil, apomorphine, trazodone, yohimbine, tramadol and dapoxetine in pharmaceutical dosage forms, counterfeit products and human plasma","volume":"10","author":"Ibrahim","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/bs.podrm.2023.11.006_bib34","unstructured":"M. Mangukiya, G. Patel, B. Rathod, D. Dhaduk, J. Maniya, Development and validation of spectroscopic methods for simultaneous estimation of avanafil and dapoxetine hydrochloride in combined dosage form. Inventi Rapid: Pharm Analysis & Quality Assurance, 2012."},{"issue":"15","key":"10.1016\/bs.podrm.2023.11.006_bib35","first-page":"9256","article-title":"Identification, synthesis and characterisation of avanafil process impurities and determination by UPLC.","volume":"12","author":"Zhao","year":"2022","journal-title":"RSC\u00a0Adv."},{"issue":"2","key":"10.1016\/bs.podrm.2023.11.006_bib36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/jssc.201800734","article-title":"Accurate and sensitive determination of sildenafil, tadalafil, vardenafil, and avanafil in illicit erectile dysfunction medications and human urine by LC with quadrupole\u2010TOF\u2010MS\/MS and their behaviors in simulated gastric conditions","volume":"42","author":"\u00d6zt\u00fcrk Er","year":"2019","journal-title":"J.\u00a0Sep. Sci."},{"key":"10.1016\/bs.podrm.2023.11.006_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2019.104302","volume":"152","author":"Er","year":"2020","journal-title":"Microchem. J."},{"key":"10.1016\/bs.podrm.2023.11.006_bib38","first-page":"783","article-title":"Detection of Avanafil and flibanserin in health food by HPLC-MS\/MS","author":"WU","year":"2017","journal-title":"Herald Med."},{"key":"10.1016\/bs.podrm.2023.11.006_bib39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.microc.2019.03.043","volume":"147","author":"Er","year":"2019","journal-title":"Microchem. J."},{"issue":"7","key":"10.1016\/bs.podrm.2023.11.006_bib40","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3390\/molecules23071771","article-title":"Development of validated and stability-indicating LC-DAD and LC-MS\/MS methods for determination of avanafil in pharmaceutical preparations and identification of a novel degradation product by LCMS-IT-TOF","volume":"23","author":"Can","year":"2018","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/bs.podrm.2023.11.006_bib41","first-page":"9485","article-title":"Detection by gas chromatography-mass spectrometry of adulterated food supplements","volume":"19","author":"Popescu","year":"2014","journal-title":"Rom. Biotechnol. Lett."},{"issue":"16","key":"10.1016\/bs.podrm.2023.11.006_bib42","doi-asserted-by":"crossref","first-page":"9407","DOI":"10.1039\/D0RA00569J","article-title":"LC-MS\/MS determination of avanafil and its metabolites in rat plasma and brain: pharmacokinetic study after oral administration and transdermal film application","volume":"10","author":"Kammoun","year":"2020","journal-title":"RSC Adv."},{"issue":"47","key":"10.1016\/bs.podrm.2023.11.006_bib43","doi-asserted-by":"crossref","first-page":"29797","DOI":"10.1039\/D1RA05492A","article-title":"Simultaneous determination of Avanafil and Dapoxetine in human plasma using liquid chromatography\/tandem mass spectrometry (LC-MS\/MS) based on a protein precipitation technique","volume":"11","author":"Abou-Omar","year":"2021","journal-title":"RSC Adv."},{"issue":"3","key":"10.1016\/bs.podrm.2023.11.006_bib44","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1556\/1326.2017.00116","article-title":"Stability-indicating HPLC method for simultaneous determination of degradation products and process-related impurities of avanafil in avanafil tablets","volume":"30","author":"Kumar","year":"2018","journal-title":"Acta Chromatogr."},{"issue":"1","key":"10.1016\/bs.podrm.2023.11.006_bib45","first-page":"1","article-title":"Comprehensive stability-indicating method development of Avanafil Phosphodiesterase type 5 inhibitor using advanced Quality-by-Design approach","volume":"11","author":"Patel","year":"2020","journal-title":"J.\u00a0Anal. Sci.\u00a0Technol."},{"issue":"3","key":"10.1016\/bs.podrm.2023.11.006_bib46","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.urology.2013.05.005","article-title":"Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomised, placebo-controlled clinical studies","volume":"82","author":"Porst","year":"2013","journal-title":"Urology"},{"key":"10.1016\/bs.podrm.2023.11.006_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2012.06.016","article-title":"Avanafil for the treatment of erectile dysfunction: a multicenter, randomised, double-blind study in men with diabetes mellitus","author":"Goldstein","year":"2012","journal-title":"In Mayo Clin.\u00a0Proc."},{"issue":"5","key":"10.1016\/bs.podrm.2023.11.006_bib48","first-page":"202","article-title":"Cognitive behavioral therapy as an adjunct treatment for Pakistani men with ED","volume":"29","author":"Khan","year":"2017","journal-title":"Int.\u00a0J.\u00a0Imp. Res."},{"issue":"8","key":"10.1016\/bs.podrm.2023.11.006_bib49","first-page":"2122","article-title":"Selectivity of Avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability","volume":"9","author":"Wang","year":"2012","journal-title":"J.\u00a0Sex. Med."},{"issue":"6","key":"10.1016\/bs.podrm.2023.11.006_bib50","first-page":"279","article-title":"Management of treatment-related sexual complications in cancer care: evidence for erectile function recovery and penile rehabilitation after radical prostatectomy in prostate cancer survivorship","volume":"2","author":"Chung","year":"2017","journal-title":"Exp. Rev.\u00a0Qual.\u00a0Life Cancer Care"},{"key":"10.1016\/bs.podrm.2023.11.006_bib51","unstructured":"Sildenafil [package insert]. New York, NY: Pfizer Labs; 2021. 11 April 2023; from \u3008https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=645\u3009."},{"issue":"9","key":"10.1016\/bs.podrm.2023.11.006_bib52","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/17512433.2016.1212655","article-title":"Avanafil for the treatment of erectile dysfunction","volume":"9","author":"Zurawin","year":"2016","journal-title":"Exp. Rev.\u00a0Clin. Pharmacol."},{"key":"10.1016\/bs.podrm.2023.11.006_bib53","unstructured":"FDA Approves First Treatment for COVID-19. US Food and Drug Administration 2022 [cited 2022 24 March]; from \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19\u3009."},{"issue":"1","key":"10.1016\/bs.podrm.2023.11.006_bib54","article-title":"Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus","author":"Vardi","year":"2007","journal-title":"Coch. Database System. Rev."}],"container-title":["Profiles of Drug Substances, Excipients and Related Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512523000201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512523000201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T15:14:56Z","timestamp":1753715696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871512523000201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443293269"],"references-count":53,"URL":"https:\/\/doi.org\/10.1016\/bs.podrm.2023.11.006","relation":{},"ISSN":["1871-5125"],"issn-type":[{"value":"1871-5125","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}